MADRIGAL PHARMACEUTICA

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

30 10 2024 08:00:22 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

21 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

18 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

02 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

01 10 2024 08:00:01 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

30 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

26 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

07 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

02 8 2024 07:00:21 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

24 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

06 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

29 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 5 2024 07:00:01 提供 Nasdaq GlobeNewswire

Madrigal Statement on the Passing of Dr. Stephen Harrison

24 4 2024 16:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

23 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

16 4 2024 16:05:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

09 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 4 2024 16:05:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

18 3 2024 23:58:56 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Proposed Public Offering

18 3 2024 16:04:05 提供 Nasdaq GlobeNewswire